We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| DMG Mori AG | AQEU:GILD | Aquis Europe | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 43.50 | 43.50 | 44.10 | 43.50 | 43.50 | 43.50 | 51 | 16:29:29 |
From Jun 2019 to Jun 2024
India's Aurobindo Pharma Ltd. (524804.BY) said Monday it has received tentative approval from the U.S. Food and Drug Administration to manufacture and sell generic combination drug emtricitabine/tenofovir disproxil fumarate tablets.
Aurobindo has received the approval for the tablets in 200-milligram and 300-mg doses, it said in a filing to the Bombay Stock Exchange.
The tablets, which are used for the treatment of HIV-1 infection in adults, are the generic equivalent of Gilead Sciences Inc.'s (GILD) truvada, the company said.
-By Ameya Karve; Dow Jones Newswires; +91-22-22884212-18; ameyaanil.karve@dowjones.com
1 Year DMG Mori Chart |
1 Month DMG Mori Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
